Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05396573
Recruitment Status : Not yet recruiting
First Posted : May 31, 2022
Last Update Posted : May 31, 2022
Sponsor:
Collaborator:
Shanghai RNACure Biopharma Co., Ltd.
Information provided by (Responsible Party):
Walvax Biotechnology Co., Ltd.

Brief Summary:
This is a phase 1b, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013 in healthy adults primed with a two-dose inactivated vaccine 6-9 months earlier. The study vaccine is administered IM in the upper arm deltoid as single booster shot on day 0.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: RQ3013 Biological: Comirnaty Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Blinded, Positive Control Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine (RQ3013) in Healthy Adults Completed a Two-dose Primary Series of Inactivated Vaccine
Estimated Study Start Date : July 2022
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RQ3013 Biological: RQ3013
A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL

Active Comparator: Comirnaty Biological: Comirnaty
A single dose of 30 μg/0.3 mL




Primary Outcome Measures :
  1. Immediate AEs within 30 minutes after booster vaccination, solicited local and systemic AEs for within 7 days and unsolicited AEs within 28 days following booster vaccination [ Time Frame: within 28 days following booster vaccination ]

Secondary Outcome Measures :
  1. Live virus GMT, GMFR and seroconversion rate against Beta and Omicron strain in serum measured at pre booster dose and day 7, 14, 28 after booster dose [ Time Frame: pre booster dose and day 7, 14, 28 after booster dose ]
  2. Pseudovirus GMT, GMFR and seroconversion rate against SARS-CoV-2 Beta and Omicron strain in serum measured at pre booster dose and day 7, 14, 28 after booster dose [ Time Frame: pre booster dose and day 7, 14, 28 after booster dose ]
  3. GMT, GMFR and seroconversion rate of S-Protein Specific IgGs in serum measured at pre booster dose and day 7, 14, 28 after booster dose [ Time Frame: pre booster dose and day 7, 14, 28 after booster dose ]
  4. Live virus GMT, GMFR and seroconversion rate against Beta and Omicron strain in serum measured at 3, 6, 12 months after booster dose [ Time Frame: 3, 6, 12 months after booster dose ]
  5. Pseudovirus GMT, GMFR and seroconversion rate against SARS-CoV-2 Beta and Omicron strain in serum measured at 3, 6, 12 months after booster dose [ Time Frame: 3, 6, 12 months after booster dose ]
  6. GMT, GMFR and seroconversion rate of S-Protein Specific IgGs in serum measured at 3, 6, 12 months after booster dose [ Time Frame: 3, 6, 12 months after booster dose ]
  7. Changes of safety laboratory measures at day 4 following booster vaccination in comparison to pre-boosting levels [ Time Frame: day 4 following booster vaccination ]
  8. SAEs and AESIs throughout the study [ Time Frame: 12 months after vaccination ]

Other Outcome Measures:
  1. Spike protein specific CD4+, CD8+, CD4+IFN-γ+, CD4+IL-2+, CD4+TNFα+, CD4+IL-4+, CD4+IL-13+, CD8+IFN-γ+, CD8+IL-2+, CD8+TNFα+ cytokine profiling (flow cytometry) by flow cytometry at baseline and day 7, 14 after booster [ Time Frame: baseline and day 7, 14 after booster ]
  2. Spike protein specific cytokine responses by enzyme-linked immunospot (ELISPOT) assay, IFN-γ, IL-2, IL-4 at baseline and day 7, 14 after booster [ Time Frame: baseline and day 7, 14 after booster ]
  3. Spike protein specific T memory cell responses: CD4+ and CD8+ TCM(CCR7+CD45RA-), TEM(CCR7-CD45RA-) and TSCM(CCR7+CD45RA+CD95+) at baseline and 28 days, 3, 6 months after booster [ Time Frame: baseline and 28 days, 3, 6 months after booster ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy participants 18-59 years and 60 years and older, and both males and females should be included;
  2. Participants who agree to participate in this clinical trial voluntarily and sign the informed consent form, are capable of providing valid identification, understanding and complying with the requirements of the clinical protocol.
  3. Participants who have been primed with a two-dose inactivated vaccine 6-9 months earlier, and the intervals between the two inactivated vaccines was between 21 and 42 days.
  4. For female participants of childbearing potential, effective contraception measures should be used within 2 weeks prior to participation in this study and the results of the pregnancy test must be negative. Participants must voluntarily agree to use effective contraceptive measures from the time of signing the informed consent form to the end of the study (effective contraceptive measures including oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.).

Exclusion Criteria:

  1. Receipt of any COVID-19 prophylactic medication other than a primary series of inactivated vaccine (e.g., receipt history of any approved or under developing COVID-19 vaccines, or other COVID-19 prophylactic medication, etc.), or non-standard primary series of inactivated vaccine;
  2. Abnormal vital signs with clinical significance at screening, with systolic blood pressure ≥140 mmHg (≥150 mmHg for participants aged ≥ 60 years) and/or diastolic blood pressure ≥90 mmHg, or axillary body temperature ≥ 37.3°C, or abnormal results of laboratory screening tests which was clinically significant at screening;
  3. Known allergy, or history of anaphylaxis or other serious adverse reactions to the study vaccine or its excipients;
  4. History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS);
  5. History of COVID-19, or history of close contact with confirmed/suspected COVID-19 patients, or positive results for SARS-CoV-2 nucleic acid tests at screening;
  6. Administration of antipyretics or painkillers within 24 hours prior to vaccination;
  7. Receipt of any live attenuated vaccine within 28 days prior to vaccination, or subunit and inactivated vaccine within 14 days prior to vaccination;
  8. Receipt of blood or blood-related products, including immunoglobulins, within 3 months prior to vaccination; or any planned use during the study period.
  9. Participants with the following diseases:

    1. Any acute diseases or acute attacks of chronic diseases within 7 days prior to enrolment;
    2. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
    3. Congenital or acquired immunodeficiency or autoimmune disease, or long-term receipt (>14 consecutive days) of glucocorticoid (reference value for dose: ≥20 mg/day prednisone or equivalent) or other immunosuppressive agents within the past 6 months, with exception of inhaled or topical steroids, or short-term use (≤14 consecutive days) of oral corticosteroids;
    4. Currently suffering from or previously diagnosed with infectious diseases, positive screening results for hepatitis B surface antigen, hepatitis C antibody, treponema pallidum antibody, human immunodeficiency virus antibody;
    5. History or family history of neurological disorders (convulsions, epilepsy, encephalopathy, etc.) or psychiatric disorders;
    6. Asplenia, or functional asplenia;
    7. Presence of severe, uncontrollable or hospitalization indicated cardiovascular diseases, diabetes, blood and lymphatic diseases, immune diseases, liver and kidney diseases, respiratory diseases, metabolic and skeletal diseases, or malignant tumors, except for history of well-controlled chronic diseases, such as diabetes, hypertension, etc.;
    8. Participants who cannot tolerate venepuncture, or have a history of needle or blood phobia;
    9. Contraindications to IM injections and blood draws, such as coagulation disorders, thrombotic or bleeding disorders, or conditions that needs continuous anticoagulant usage.
  10. Drug or alcohol abuse (alcohol intake ≥ 14 units per week) which in the investigator's opinion would compromise the participant's safety or compliance with the study procedures;
  11. History of a major surgery, per the investigator's judgment, within 12 weeks before vaccination, or not achieving full recovery after surgery, or any planned major surgery during the study;
  12. Pregnant or lactating females; males whose partner plans to conceive; males or females who plan to donate sperm or eggs;
  13. Participating or planning to participate in other clinical trials during the study period;
  14. Presence of any underlying disease or condition which, in the opinion of the investigator, may place the participant at unacceptable risk, make the participant unable to meet the requirements of the protocol, or interfere with the assessment of vaccine response.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05396573


Contacts
Layout table for location contacts
Contact: Shuyuan Yang (+86)18687832269 ynwsysy@walvax.com

Sponsors and Collaborators
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Lin Yuan Walvax Biotechnology Co., Ltd.
Layout table for additonal information
Responsible Party: Walvax Biotechnology Co., Ltd.
ClinicalTrials.gov Identifier: NCT05396573    
Other Study ID Numbers: RQ3013-005
First Posted: May 31, 2022    Key Record Dates
Last Update Posted: May 31, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases